<DOC>
	<DOC>NCT02543918</DOC>
	<brief_summary>The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus. This study will last about 6 weeks with follow-up at 12 weeks.</brief_summary>
	<brief_title>A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy males and females without compromised immune system Have a body mass Index of 18 to 32 kilograms per square meter (kg/mÂ²) Previously completed or withdrawn from an ixekizumab study or a study investigating interleukin17 (IL17) antagonists Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long halflife, 3 months or 5 halflives (whichever is longer) should have passed Have known allergy or hypersensitivity to any biologic therapy Past vaccination allergy or Arthustype hypersensitivity Received a tetanus toxoidcontaining vaccine within the last 5 years Severe allergic reaction to Boostrix Allergic to latex Have been immunized with pneumococcal vaccine Known hypogammaglobulinemia History of GuillainBarre Syndrome Active infectious disease Had a live vaccination within 1 year prior to screening, or intend to have a live vaccination during the course of the study Evidence of a significant uncontrolled neuropsychiatric disorder Have a score of 3 on Item 12 of the Quick Inventory of Depressive SymptomatologySelf Report (16 Items) at screening Evidence of Human Immunodeficiency Virus infection, Hepatitis C, B Had symptomatic herpes zoster within 3 months of screening Women who are lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>